← Leaderboards
John Sfakianos
Icahn School Of Medicine At Mount Sinai
$1,435,953
Attributed
$3,100,198
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$3,100,198 · 3
By mechanism
R01$2,675,533 · 2
R21$424,665 · 1
Top collaborators
- Amir Horowitz6 shared
- Won-Min Song1 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Amir Horowitz$1,902,078
- Lucas Ferrari De Andrade$1,481,935
- Nihal Mohamed$3,339,381
- Richard Silvera$369,313
- Cheng Zhang$6,068,855
Others in their field
Other Rising Stars on “Tumor”
- Kenneth Schultz · Trethera Corporation$7,146,643
- Jeff P Simko · Washington University$4,848,843
- Gary G Schwartz · University Of North Dakota$4,000,000
- Yicheng Wang · Immunova Therapeutics, Llc$4,000,000
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
- Daniel Francis · Claria Medical, Inc.$3,708,259
Research focus
TumorHigh RiskPathway InteractionsTranscriptome SequencingTumor MicroenvironmentSignal TransductionMalignant Neoplasm Of Urinary BladderNon-Muscle Invasive Bladder CancerResponseTherapy ResistantTumor ImmunityBindingBladder NeoplasmBcg LiveIntravesicalIn VitroNewly DiagnosedCellsResistanceResistance MechanismCytokineInflammatoryComplexInfiltration
Grant awards (6)
Multi-scale analysis of Bacillus Calmette-Guérin (BCG) resistant tumor micro-environment in non-muscle invasive bladder cancer to identify novel therapeutic axis$684,877
R01 · FY2025 · CA
HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer$667,174
R01 · FY2025 · CA
HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer$637,395
R01 · FY2024 · CA
Identifying novel resistance mechanisms in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)$187,642
R21 · FY2024 · CA · contact PI
HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer$686,087
R01 · FY2023 · CA
Identifying novel resistance mechanisms in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)$237,023
R21 · FY2023 · CA · contact PI